Literature DB >> 12554099

Structure-function relationships in factor IX and factor IXa.

Amy E Schmidt1, S Paul Bajaj.   

Abstract

Factor IX (FIX) consists of an N-terminal gamma-carboxyglutamic acid (Gla) domain followed by two epidermal growth factor (EGF)-like domains, and the C-terminal serine protease domain. During physiologic coagulation, one of the activators of FIX is the FVIIa/tissue factor (TF) complex. In this reaction, the Gla and EGF1 domains of FIX are thought to interact with TF. The FIXa that is generated then combines with FVIIIa on the platelet surface to activate FX in the coagulation cascade. In this assembly, the protease domain and possibly the EGF2 domain of FIXa are thought to provide the primary specificity in binding to FVIIIa. Disruption of the interaction of FIX/FX with TF and of the FIXa:FVIIIa interface may provide a pharmacologic target as an alternative strategy for the development of antithrombotic agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554099     DOI: 10.1016/s1050-1738(02)00210-4

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  16 in total

1.  Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Authors:  Amy E Schmidt; Kanagasabai Vadivel; Julian Whitelegge; Satya Paul Bajaj
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

2.  Correlation of factor IXa subsite modulations with effects on substrate discrimination.

Authors:  P F Neuenschwander; K J Deadmond; K Zepeda; J Rutland
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

Review 3.  Recent advances in hemophilia B therapy.

Authors:  Sarena D Horava; Nicholas A Peppas
Journal:  Drug Deliv Transl Res       Date:  2017-06       Impact factor: 4.617

Review 4.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Contribution of the NH2-terminal EGF-domain of factor IXa to the specificity of intrinsic tenase.

Authors:  Shabir H Qureshi; Likui Yang; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

Review 6.  Aptamers as therapeutics in cardiovascular diseases.

Authors:  P Wang; Y Yang; H Hong; Y Zhang; W Cai; D Fang
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 7.  Update on the physiology and pathology of factor IX activation by factor XIa.

Authors:  Stephen B Smith; David Gailani
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

8.  Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X.

Authors:  L Yang; C Manithody; A R Rezaie
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

9.  Role of magnesium in factor XIa catalyzed activation of factor IX: calcium binding to factor IX under physiologic magnesium.

Authors:  S Agah; S P Bajaj
Journal:  J Thromb Haemost       Date:  2009-06-03       Impact factor: 5.824

Review 10.  Exosites in the substrate specificity of blood coagulation reactions.

Authors:  P E Bock; P Panizzi; I M A Verhamme
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.